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Introduction
Klotho is a circulating anti-ageing hormone with anti-oxi-
dative and anti-inflammatory properties that has demon-
strated vascular protective effects in animal studies.1 
Recent data suggests that low levels of circulating Klotho 
predicts increased risk of progression of cardiovascular 
and renal disease.2 The role of Klotho in predicting pro-
gression of diabetic retinopathy has not been studied and is 
currently unknown.
Material and methods
We performed a single-centre observational follow-up 
study of 81 patients with type 2 diabetes followed for a 
median of 44  (interquartile range (IQR) 21.5–62.0) 
months. The primary outcome was progression of retin-
opathy defined as new onset retinopathy or step change in 
retinopathy grading. In view of the lack of previous studies 
in this area and to generate future sample size calculations, 
we chose this pragmatic composite endpoint for our proof 
of concept study.
Retinopathy was evaluated by monoscopic fundus pho-
tos of dilated pupils using a nonmydriatic camera. Digital 
retinal images were graded according to the United Kingdom 
National Health Service Diabetic Eye Screening Programme. 
Serum levels of Klotho, phosphorus, calcium, vitamin D 
and fibroblast growth factor-23 (FGF-23) levels were meas-
ured from stored samples collected at baseline as described 
previously.3 None of the patients were on vitamin D, cal-
cium or phosphate supplements at baseline. All patients had 
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an estimated glomerular filtration (eGFR) rate of >30 ml/
min by Modification of Diet in Renal Disease (MDRD) 
Study equation. Clinical, biochemical and anthropometric 
data were collected from electronic health records.
Descriptive statistics were used for the analysis of 
demographic and clinical features of the cohort. Klotho 
levels were log transformed before calculation because 
of their positively skewed distribution. Between-group 
differences were compared by unpaired t test (for con-
tinuous parametrically distributed variables) and Mann-
Whitney test (for continuous non-parametrically 
distributed variables). A χ2 test was used to compare 
categorical variables between groups. Multivariate 
logistic regression analysis was performed to evaluate 
the variables significantly associated with progression 
of retinopathy. Data are given as mean ± SD, percent-
age for categorical variables, or median and IQR for 
variables not normally distributed. A two-tailed p value 
<0.05 was considered significant. Statistical analyses 
were performed with SPSS version 25.0 (SPSS, 
Chicago, IL, USA).
Results
The mean age (range) of our cohort was 61 (48–78) years 
with a median diabetes duration of 11.8 years. Patients 
were predominantly male (62%) and 91% were on renin 
angiotensin aldosterone system (RAAS) blockade. 
Baseline median (IQR) circulating serum Klotho level was 
265 (184.7–567.78) pg/ml.
At baseline, 47 (58%) patients had evidence of diabetic 
retinopathy. Of these 47 patients with baseline retinopathy, 
the majority (80%) had background retinopathy, with the 
remainder having pre-proliferative (10%) or proliferative 
(10%) retinopathy respectively.
During the follow up observation period, 46 (57%) 
patients reached the primary endpoint of progression of 
retinopathy.
Table 1 details selected clinical and biochemical vari-
ables between patients with retinopathy progression as 
compared to those without progression. Patients with 
progression of retinopathy as compared to those without 
were similar in clinical features including HbA1c, serum 
phosphate, FGF-23, vitamin D levels, demographics and 
traditional risk factors for retinopathy (Table 1). 
However, we observed the novel finding of lower levels 
of circulating Klotho (median (IQR) 226.9 (171.1–
394.0) vs 484.5 (221.8–709.9) pg/ml, p = 0.001) in 
patients with progression of retinopathy as compared to 
those without. The only other parameters that were sig-
nificantly different between the two groups were serum 
calcium and eGFR (Table 1). There were no significant 
differences observed in biomarkers and markers of vas-
cular inflammation and oxidative stress associated with 
retinopathy such as oxidized low-density lipoprotein 
(ox-LDL), high sensitivity C reactive protein (hsCRP) 
Table 1. Selected baseline clinical and biochemical variables in a cohort of 81 patients with diabetes with and without progression 
of diabetic retinopathy.





Age, years 60.7 ± 9.3 61.2 ± 8.8 0.79
Duration of diabetes, years 13.8 ± 8.2 12.7 ± 11.1 0.62
RAAS blockade 89% 93% 0.44
BMI, kg/m2 32.3 ± 6.0 32.6 ± 6.4 0.81
HbA1c, % (mmol/mol) 7.7 ± 1.4 (61 ± 7) 7.6 ± 1.4 (60 ± 7) 0.67
SBP, mmHg 151.6 ± 16.5 156.7 ± 13.9 0.13
DBP, mmHg 79.6 ± 10.0 81.5 ± 9.6 0.40
eGFR, ml/min/1.73 m2/year 69.0 ± 27.3 81.7 ± 23.7 0.03
Total cholesterol, mmol/l 4.3 ± 1.0 4.3 ± 1.1 0.94
Klotho, pg/ml* 484.5 (221.8–709.9) 226.9 (171.1–394.0) 0.001
FGF-23, RU/ml 56.5 ± 42.4 58.9 ± 32.2 0.81
Serum calcium, mg/l 2.3 ± 0.1 2.4 ± 0.1 0.02
Phosphate, mmol/l 1.1 ± 0.2 1.1 ± 0.4 0.45
25 vitamin D, ng/ml 44.8 ± 20.3 35.9 ± 21.6 0.12
hsCRP, mg/l** 4.7 ± 5.1 4.0 ± 4.7 0.61
VCAM-1, ng/ml** 508.3 ± 204.2 606.9 ± 276.3 0.36
Ox-LDL, U/l** 48.9 ± 22.0 48.2 ± 20.6 0.61
BMI: body mass index; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; RAAS: renin 
angiotensin aldosterone system; FGF-23: fibroblast growth factor 23; hsCRP: high sensitivity C reactive protein; VCAM-1: vascular cellular adhesion 
molecule-1; Ox-LDL: oxidized low-density lipoprotein.
Mean ± SD, n (%) or * median (interquartile range).
**Results available for sub-group of 54 patients (n = 17 without progression and n = 37 with progression of retinopathy).
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and vascular cell adhesion molecule (VCAM-1) between 
the two groups (results were available for sub-group of 
54 patients). Neither duration of follow-up nor severity 
of retinopathy at baseline were determinant factors for 
progression of retinopathy.
The number of patients who developed the individual 
components of the composite retinopathy endpoint were 
24 for new onset retinopathy and 22 for progression of 
retinopathy respectively. In post-hoc analyses, we did not 
observe a significant effect of soluble Klotho levels on 
these individual components of the primary composite 
endpoint. Of the cohort of 81 patients, 22% (n = 18) had 
diabetic maculopathy at baseline and we did not observe 
any significant association between Klotho levels and pro-
gression of maculopathy.
In multivariable logistic regression analyses, baseline 
log Klotho levels was the only variable independently 
associated with reduced risk of progression of retinopa-
thy (OR 0.067, 95% CI 0.006–0.693, p = 0.015). Serum 
calcium and eGFR were not significantly associated with 
retinopathy progression. Our results suggest that a halv-
ing of circulating Klotho levels increases the risk of 
retinopathy progression by 44%. The significant effect of 
Klotho was also independent of traditional risk factors 
for retinopathy progression (e.g. systolic and diastolic 
blood pressure measures, HbA1c, duration of diabetes) in 
multivariable analyses.
Discussion
There is limited information on Klotho and diabetic retin-
opathy in the literature. In one recent cross-sectional 
study by Ji et al.4 in 60 patients with diabetes (of whom 
33 had diabetic retinopathy), the authors observed that 
more advanced stages of diabetic eye disease were asso-
ciated with lower circulating Klotho levels and that 
Klotho pre-treatment ameliorated palmitic acid induced 
apoptosis in human retinal endothelial cells. Limitations 
of the study was the inclusion patients with advanced 
renal disease, lack of information on concomitant medi-
cation (such as RAAS) which influence klotho levels and 
absence of prospective data.
In a study by Słomiński et al.,5 Klotho gene polymor-
phism were observed to protect against the development of 
retinopathy in patients with type 1 diabetes and the poly-
morphism was associated with lower levels of inflamma-
tory markers, pro-angiogenic factors and adhesion 
molecules. The authors hypothesised that their results may 
be related to increased Klotho protein levels or activity of 
the protein which could protects against microvascular 
inflammation and endothelial dysfunction that drive onset 
and progression of retinopathy.
The strengths of our study include the use of stand-
ardised and robust diabetic eye screening data from 
digital records with the long term follow up in a well 
characterised cohort of type 2 diabetes. We also meas-
ured several emerging markers of retinopathy risk such 
as VCAM-1, ox-LDL, hsCRP in a sub-group of patients 
and other hormones associated with Klotho such as 
FGF-23 and vitamin D which were not significantly dif-
ferent between groups. HbA1c was similar in the two 
groups. We excluded patients with advanced kidney dis-
ease and those on treatment with vitamin D, calcium or 
phosphate supplements or binders as this may influence 
Klotho and FGF23 levels and could confound interpre-
tation of the results. The limitations of our study are the 
relatively small sample size, the single centre design 
and the lack of additional measures of angiogenic mark-
ers/inflammatory mediators in the full cohort. The pri-
mary retinopathy endpoint of our study was a composite 
of new onset retinopathy or step change in retinopathy 
grading. A further limitation of our study was that, pos-
sibly due to the small sample size, we were unable 
determine the effects of Klotho on these individual 
components. Further larger studies are required to deter-
mine the effect of Klotho levels on these distinct retin-
opathy endpoints. Our observations and results establish 
the rationale for future work in this important area. Our 
study was also not designed to explain the potential 
pathophysiology between circulating Klotho level per-
turbations and progression of retinopathy. We speculate 
that the well-established anti-inflammatory, anti-oxida-
tive and anti-apoptotic vascular effects of Klotho may 
also protect against diabetic endothelial dysfunction 
and microvascular damage that characterise diabetic 
retinopathy, however further mechanistic studies are 
required to explain our findings.
In conclusion, in our cohort of people with type 2 dia-
betes, lower circulating levels of the vascular protective 
hormone Klotho are associated with increased risk of new 
onset and progression of diabetic eye disease. Klotho may 
be a novel biomarker of diabetic retinopathy and a poten-
tial treatment target for diabetic eye disease.
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